Asahi Kasei unifies global pharma business to target US$1.9B in revenue by 2030
It is now integrating those businesses under Asahi Kasei Therapeutics, the name of its existing Japanese pharmaceutical unit.
JAPAN— Asahi Kasei is consolidating its pharmaceutical businesses under one global brand in Japan to streamline operations, strengthen licensing activity and reach 300 billion yen (US$1.9 billion) in annual revenue by fiscal 2030.
The Tokyo based conglomerate has expanded its pharmaceutical portfolio through acquisitions since 2020, building a presence across specialty medicines and adding products and development programmes in several therapeutic areas.
It is now integrating those businesses under Asahi Kasei Therapeutics, the name of its existing Japanese pharmaceutical unit.
Acquisitions underpin global expansion
Asahi Kasei entered the US pharmaceutical market in 2020 by acquiring Veloxis Pharmaceuticals.
The deal added Envarsus XR, a treatment used to prevent organ rejection in kidney transplant recipients, to its portfolio.
In 2024, the company expanded its reach in kidney disease through the acquisition of Swedish biopharmaceutical company Calliditas Therapeutics in a deal valued at about $1 billion.
Calliditas markets Tarpeyo, a treatment for immunoglobulin A nephropathy, a progressive kidney disease.
Asahi Kasei continued its expansion in February 2026, when it agreed to acquire Germany’s Aicuris Anti-infective Cures for about US$920 million.
The transaction extended its presence into infectious disease drug development and added expertise in antiviral medicines.
Until the latest restructuring, the acquired businesses retained their individual identities.
Under the new arrangement, they will operate as Asahi Kasei Therapeutics, bringing the pharmaceutical operations under a unified global management structure.
Unified management to support licensing and investment
Yoshikazu Aoki, global president of Asahi Kasei Therapeutics, said the structure would enable the company to allocate resources across its pharmaceutical business rather than manage them separately by company or region.
He also said the arrangement would strengthen its ability to pursue in licensing opportunities.
Asahi Kasei plans to invest approximately 40 billion yen (US$250 million) in in licensing over the next three years.
The investment is intended to expand its pipeline alongside further mergers and acquisitions as the company works towards its fiscal 2030 revenue target.
The strategy reflects the role that external innovation can play in pharmaceutical growth.
Licensing agreements allow companies to obtain rights to medicines developed by other organisations, potentially broadening their portfolios without having to discover and develop every product internally.
Acquisitions can provide access to established commercial medicines, clinical development programmes and specialised research capabilities.
For Asahi Kasei, a common management structure could also help decision makers assess investment opportunities across therapeutic areas and regions.
The company has not detailed how the consolidation will affect individual operations or whether it will result in changes to staffing or research priorities.
Focus on specialty medicines
Asahi Kasei focuses on immunology, nephrology, transplantation and infectious diseases.
Its existing products and acquired programmes provide a base for growth in these areas, while planned licensing deals could introduce additional candidates and commercial opportunities.
Aicuris brings a distinct infectious disease portfolio.
The German company receives royalties from sales of Prevymis, a cytomegalovirus medicine licensed to Merck & Co., and is developing treatments targeting infectious diseases, including herpes simplex virus.
The combined portfolio gives Asahi Kasei exposure to both marketed therapies and medicines in development.
Its planned licensing investment and further acquisition activity will support efforts to expand that portfolio as the company pursues its 2030 revenue target.
Be the first to leave a comment